assessing immunotherapy in various subtypes of lung cancer
Published 2 years ago • 166 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
4:15
the toxicities associated with immunotherapy in lung cancer patients
-
1:30
treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
-
1:08
toxicities of immunotherapy and patient expectations in lung cancer
-
1:24
acquired resistance: facing the challenge of immunotherapy in patients with lung cancer
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
1:54
balancing the benefits and costs of immunotherapy in the treatment of lung cancer
-
1:51
future directions for neoadjuvant immunotherapy in lung cancer
-
1:19
developments in immunotherapy for lung cancer
-
3:46
understanding immunotherapy for lung cancer
-
1:30
immunotherapy in second-line treatment of non-small cell lung cancer
-
19:59
biologic basis of immunotherapy in lung cancer
-
2:46
unanswered questions in treating lung cancer with immunotherapy
-
1:48
unanswered questions in lung cancer immunotherapy
-
2:19
updates in immunotherapy and mrna vaccines in lung cancer
-
2:33
lung cancer: post-frontline immunotherapy
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
5:25
immunotherapy in lung cancer